|Update on TS clinical trial plans|
|Study design trials and tribulations||Dr. Dan Sargent
Dr. Richard Schilsky
|Discussion — Potential problems in designing marker-guided trials|
|Development of agents that target EGFR and related signaling pathway components|
|EGFR and cell signaling —
What we know and the agents in the pipeline
|Dr. Janet Dancey|
|EGFR assay development||Dr. Barbara Conley|
|General discussion of EGFR and the laboratory assay issues associated with development of molecular targets|
|Tissue micro-arrays and their use in the clinical laboratory|
|How will molecular signatures/profiles be translated to the clinic?|
|Progress report from the Director’s Challenge and related research||Dr. James Jacobson|
What are the likely clinical uses of signature/profile information?
Will the ongoing research move toward these uses?
What other studies will be needed?
What resources will be needed?